earnings
confidence high
sentiment positive
materiality 0.85
ANI Pharma Q4 net rev $190.6M (+44.8%), adj EPS $1.63; raises 2025 guidance
ANI PHARMACEUTICALS INC
2024-FY EPS reported
-$1.04
revenue$614,376,000
- Record Q4 net rev $190.6M (+44.8% YoY); organic growth (ex-Alimera) +23.8%.
- Rare Disease rev $87.0M: Cortrophin Gel $59.4M (+42.3%), ILUVIEN/YUTIQ $27.6M.
- Adj. non-GAAP EBITDA $50.0M (+65.7%); diluted GAAP loss per share $0.55.
- Adj. non-GAAP diluted EPS $1.63 vs $1.00 in prior year quarter.
- 2025 guidance raised: rev $756-776M, adj. EBITDA $190-200M, adj. EPS $6.12-6.49.